Genedrive (GB:GDR) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genedrive PLC is set to release its preliminary results for the fiscal year ending June 2024, with a live presentation scheduled for December 2nd. The company is spearheading advancements in pharmacogenetic testing with innovative products like the Genedrive® MT-RNR1 and CYP2C19 ID Kits, which have been endorsed for use by the UK NHS to enhance patient care. With a strategy focusing on market growth and strategic expansions, Genedrive aims to solidify its position in the healthcare diagnostics sector.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.